Data were from a final four-year analysis (up to Week 216) of the open-label extension trial of a VILTEPSO Phase 2 study NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Dr. Toru Nakai) PARAMUS, N….
